Aclaris Therapeutics Announces Issuance of U.S. Patent Covering a JAK Inhibitor for Treating Hair Loss Disorders

Pharmaceutical Investing

Aclaris Therapeutics (NASDAQ:ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,895,301, which is directed to methods related to the use and administration …

Aclaris Therapeutics (NASDAQ:ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,895,301, which is directed to methods related to the use and administration of a certain janus kinase (JAK) inhibitor for treating hair loss disorders.

As quoted in the press release:

“We are extremely pleased with the continued development of the patent portfolio we exclusively licensed from Columbia.  This new issuance continues to expand the breadth and depth of our JAK inhibitor intellectual property portfolio covering methods of use for certain JAK inhibitors for the treatment of hair loss disorders. The issuance of this patent is another step in the development of a robust patent portfolio relating to JAK inhibition and hair loss,” said Dr. Neal Walker, President and Chief Executive Officer of Aclaris.

Click here to read the full press release.

The Conversation (0)
Ă—